• By

Mayo Clinic Study Finds Immunotherapy May be Option Challenging Breast Cancer

June 2, 2014

3086990_096_(Electronic_Presentation)[1]

PHOENIX — A promising new study from Mayo Clinic, in conjunction with Caris Life Sciences, points to immunotherapy as a possible treatment option for patients with the difficult-to-treat triple negative breast cancer mutation. The study was presented this week at the 50th annual meeting of the American Society of Clinical Oncology in Chicago.

“This study may change our ability to treat triple negative breast cancer patients,” says Barbara Pockaj, M.D., lead investigator of the study and Mayo Clinic surgeon. “We may have signs that these patients can be treated with immunotherapy. We don’t have a lot of options for these patients and this would really expand our options.”

Triple negative breast cancer is an aggressive form of breast cancer that evades the immune system because it lacks expression of genes for estrogen receptor, progesterone receptor and HER2. This limits treatment options. The study examined biomarkers involved in immune evasion including the gene PD-L1 and its association with other biological pathways as potential treatment options. In other cancers, patients who have the PD-L1 gene have been treated with immunotherapy – enhancing the body’s immune system – and some of the results have been dramatic, Dr. Pockaj says.

"This is important because immunotherapy is evolving as an effective treatment for patients with cancer,” she says. “We’ve seen remarkable results with patients with melanoma, renal cell carcinoma and even lung cancer. The question is, ‘Can we expand this type of treatment to patients with breast cancer?’"

The study analyzed 511 triple negative breast cancer samples using a multiplatform approach, including whole genome mRNA expression, protein expression, gene copy number changes and gene sequencing. The study found that 25 to 30 percent had the PD-L1 gene, which means those patients may be candidates for immunotherapy. There is a suggestion that the percentage may be even higher for patients who carry the BRCA1 gene, which produces tumor suppressor proteins. While the results need further investigation, they illustrate how molecular profiling can be used to identify potential treatment targets in triple negative breast cancer and other difficult-to-treat cancers.

“We now want to do validation studies in which we would hope to determine whether those patients who overexpress PD-L1 also have changes in their DNA repair genes,” Dr. Pockaj says. “And if they have both, it suggests the combination immunotherapy and chemotherapy may work.”

Gargi Basu, Ph.D., was the investigator from Caris Life Sciences.

###

About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, http://www.mayoclinic.org and newsnetwork.mayoclinic.org.

Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.

MEDIA CONTACT: Jim McVeigh, Mayo Clinic Public Affairs, 480-301-4222, mcveigh.jim@mayo.edu.

I see so many signatures that are out of compliance with 2 or more of these guidelines. As if the folks who really need to read it never see it…

COMMENT

Lynn, you could ask their supervisor to remind the entire work unit and include a link to the article.

COMMENT

Are these just recommended guidelines, or are these the mandatory guidelines that must be followed? A few months ago when email signatures were talked about, it sounded like these were just recommendations. Also, does every Mayo employee need to have an email signature?

COMMENT

How about approved titles after the name. Is there an official list of approved titles (MD, PhD, RN, etc.) that can be listed or linked to. It seems like it is alphabet soup after some peoples names (like FHIMSS)

COMMENT

Can an existing signature be edited or must a person delete the existing signature and create a new one to make changes? I use Outlook 2003, but this may apply to Outlook 2010 also.

COMMENT

Is there a way to make your signature saved within outlook so it will appear on all emails, not just the ones sent from one computer? Working on many different computers it is time consuming to add it every time.

COMMENT

Andrew, I think we're only supposed to add what's on our badge.

COMMENT

We were instructed a few years ago that we must include the tag line "This information is confidential and legally protected from discovery by applicable Arizona statutes (e.g., ARS §36.445, ARS §36.445.01 and ARS §36.2403)." Has this changed? When did it change?

COMMENT

There are so many people using mobile divices for internal and external email I think you should consider guildlines for mobile devices. For example when you get a new phone the set up says "sent using Ipad, or sent using Samsung Droid" seems they should say, sent via mobile device so the ready knows why the email looks so screwed up when they read it. As well have your full name in the signature line. All phones should be able to support this function.

COMMENT

@ The Editor – Can you clarify why the approved credential list you linked above is different from the one on the brand standards page found here (http://mayoweb.mayo.edu/brand-standards/Documents/credentials.pdf) ? I would assume the one on the brand st

COMMENT

How about a template in Word? Or a web app that generates the appropriate signature, after entering a lanID? The Outlook 2010 document, page 2 states "Appropriate Horizontal Format", where it should state "Appropriate Vertical Format".

COMMENT
Please login or register to post a reply.